Home > Oncology > ASCO GI 2023 > Sorafenib plus TACE may control HCC after resection

Sorafenib plus TACE may control HCC after resection

Presented By
Prof. Ming Kuang, The First Affiliated Hospital, China
Conference
ASCO GI 2023
The postoperative adjuvant combination therapy of sorafenib plus transarterial chemoembolization (TACE) proved to be superior to sorafenib alone in patients with hepatocellular carcinoma (HCC) and portal vein tumour thrombus (PVTT) after surgery in a phase 3 study. Prof. Ming Kuang (The First Affiliated Hospital, China) and colleagues designed a phase 3 trial to assess the efficacy and safety of sorafenib plus TACE as a post-operative adjuvant treatment in patients with HCC and PVTT after surgery (n=158) [1]. The included patients were randomised 1:1 to sorafenib only or to sorafenib plus TACE. Recurrence-free survival (RFS) was the primary endpoint of the trial. The RFS was significantly improved in patients receiving the combination therapy compared with those receiving sorafenib only (median RFS 16.8 months vs 12.6; HR 0.57; Log-rank P=0.0024). The median overall survival was longer in patients in the sorafenib plus TACE arm than in patients in t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on